PT - JOURNAL ARTICLE AU - Panthagani, Kristen M. AU - Hoffman, Kristi L. AU - Oluyomi, Abiodun AU - Sotelo, Jesus AU - Stewart, Christopher AU - Armstrong, Georgina AU - Luo, Dan Na AU - Bondy, Melissa AU - Walker, Cheryl Lyn AU - Petrosino, Joseph F. TI - Butyrate-producing gut bacteria are associated with protection from allergic symptoms after Hurricane Harvey AID - 10.1101/2021.12.09.21267553 DP - 2021 Jan 01 TA - medRxiv PG - 2021.12.09.21267553 4099 - http://medrxiv.org/content/early/2021/12/11/2021.12.09.21267553.short 4100 - http://medrxiv.org/content/early/2021/12/11/2021.12.09.21267553.full AB - Hurricane Harvey caused record-breaking, catastrophic flooding across the city of Houston. After floodwaters receded, several health concerns arose, including the potential adverse impact of exposure to mold in flooded homes. We rapidly launched the Houston Hurricane Harvey Health Study to evaluate if microbiome sampling in the wake of a disaster could inform flood-associated environmental exposures and adverse health outcomes. We enrolled a total of 347 subjects at 1-month and 12-months post-Harvey, collecting human (stool, nasal, saliva) and environmental (house swab) samples to profile the bacterial and fungal microbiota. Here we show reported exposure to mold was associated with increased risk of allergic symptoms for up to one year post-disaster, and that butyrate-producing bacteria in the gut were linked to protection from allergic symptoms in mold-exposed individuals. Together, these data provide new insights into how microbiome:environment interactions may influence health in the setting of a flood-related disaster.Competing Interest StatementThe authors have declared no competing interest.Funding StatementFunding for this study included the National Institute of Environmental Health Sciences (NIEHS) Mechanism for Time-Sensitive Research Opportunities in Environmental Health Sciences (R21ES029616 to MB and 478 AO, R21ES029493 to JFP and CLW); BCM Dan L. Duncan Comprehensive Cancer Center, Vivian L. Smith Foundation, 5F30HD090891-03 to KMP, and P30ES030285 to CLW.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Leveraging an existing disaster protocol at Oregon State University, rapid IRB approval was obtained at Baylor College of Medicine, and University of Texas Health Science Center obtained reciprocal approval.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.Yes16S-V4, ITS2, and WGS metagenomic data will be made available in a publicly accessible repository. Accompanying metadata will be made available, though some variables will be filtered and/or collapsed to maintain subject confidentiality.